PM8002 in the Treatment of Patients With Advanced Solid Tumors
ConditionMalignant Neoplasm
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorBiotheus Inc.
About this trial
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of PM8002, a PD-L1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumors.
Eligibility criteria
Qualifiers
Voluntary participation in clinical study; fully understand the study and sign informed consent voluntarily; willing to follow and able to complete all test procedures;
Male or female aged 18 to 75 years;
Patients with malignant tumor confirmed by histology or cytology;
The toxicity of previous anti-tumor therapy has not been alleviated；
Disqualifiers
History of severe allergic disease, severe allergy to drugs or known allergy to any component of the drug in this study;
Evidence of major coagulopathy or other obvious risk of bleeding;
Patients are experiencing a clear interstitial lung disease or non-infectious pneumonia, unless it is caused by local radiotherapy;
Patients with uncontrolled brain metastases should be excluded from this clinical trial;
Trial design
Treatments tested in this trial
- PM8002
Treatment groups
380 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov